|
Kitazato Corporation is a medical device and reagent manufacturer specializing in reproductive engineering technologies for assisted reproduction, including artificial insemination and in vitro fertilization. The company develops and produces products for the entire IVF workflow, covering oocyte and sperm collection, washing, fertilization, culture, and cryopreservation. Key products include the Cryotop and Cryotop-CL cryovials, Ova Cryo Sheet, ET catheters, IUI catheters, OPU needles, and various media and reagents such as HTF medium and vitrification solutions. The group operates through subsidiaries Kitazato BioScience, Kitazato Testing Center, Kitazato Healthcare, and Kitazato Cryobank, with Kitazato America, Inc. handling distribution and regulatory affairs in the United States. Kitazato supplies hospitals and clinics in Japan and globally via a network of distributors. The company manufactures all products in Japan, utilizing manual craftsmanship to produce customized micro-tools and glass pipettes for ICSI and assisted hatching. It collaborates with universities and clinics worldwide for joint research and development, particularly in ultra-rapid vitrification technology. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Medical Devices | Homepage kitazato.co.jp |
| Sector Healthcare | IR page kitazato.co.jp/en | |
|
Tags
reproductive medicine, in vitro fertilization, cryopreservation, assisted reproduction, medical reagents, glass pipettes, catheters, vitrification, icsi, fertility treatment, Kitazato BioScience, Kitazato Testing Center, Kitazato Healthcare, Kitazato Cryobank, Kitazato America Inc., Cryotop, Cryotop-CL, Ova Cryo Sheet, ET catheter, IUI catheter, OPU needle, ICSI Injection Pipette, ICSI Holding Pipette, PZD Needle, HTF medium, Biomedical Supply S.L., Biomedical Supply US Inc.
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 57.08B |
| Market cap (USD) | $ 356.754M |
| P/E | 13.86 |
| PEG | 2.80 |
| P/BV | 2.73 |
| P/S | 4.88 |
| P/OCF | 13.58 |
| P/FCF | 14.24 |
| Dividend yield | 2.9% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 20.1% |
| ROI | 19.0% |
| ROIC | 18.8% |
| Profit margin | 35.6% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 4.9% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 27.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Balance sheet detail | |||
| Trade receivables (JPY) | 1.19B | 1.46B | 1.56B |
| ↳ YoY growth | +22.9% | +7.0% | |
| Cash and deposits (JPY) | 10.5B | 11.5B | 13.4B |
| Intangible assets (JPY) | 78M | 61M | 47M |
| Cash flow detail | |||
| Operating cash flow (JPY) | 4.5B | 3.53B | 3.87B |
| Purchases of property, plant and equipment (JPY) | -76M | -899M | -239M |
| Purchases of intangible assets (JPY) | -9M | -4M | — |
| Change in receivables (cash effect) (JPY) | 320M | -271M | -102M |
| Change in inventories (cash effect) (JPY) | -262M | 173M | -209M |
| Change in payables (cash effect) (JPY) | -32M | 116M | -64M |
| Dividends paid (cash effect) (JPY) | -2B | -1.6B | -1.64B |
| Interest paid (cash effect) (JPY) | -1M | -1M | -1M |
| Income taxes paid (cash effect) (JPY) | -1.74B | -2.26B | -1.87B |
| Operating cash flow before change in receivables (JPY) | 4.18B | 3.8B | 3.97B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | 4.42B | 2.62B | 3.63B |
| Income detail | |||
| Research and development expense (JPY) | 8M | 3M | 14M |
| Total comprehensive income (JPY) | 3.97B | 3.79B | 3.9B |
| Comprehensive income to owners (JPY) | 3.97B | 3.79B | 3.9B |
| Reported | Jun 30, 2025 | Jun 30, 2025 | Jun 24, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.




